Taiho Pharmaceutical Co., Ltd.Araris Biotech AGTaiho Pharmaceutical to Acquire Next-Generation ADC Drug Discovery Company Araris ...

A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentations have concluded.

ADCs are designed to selectively deliver cytotoxic drugs (payloads) to cancer cells by attaching them to antibodies that bind specifically to cancer cells through linkers. Foundational to its ...

(Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said ...

The ODT-ADS-7B64G-3 is an ultra-high-bandwidth time-interleaved ADC designed in a 3nm CMOS process. This 7-bit, 64GSPS ADC supports ac-coupled input signals up to Nyquist and features a full-scale ...

The Company's AraLinQ™ technology enables the attachment of multiple, synergistic cancer-fighting payloads to a single antibody in an efficient one-step process, whilst ensuring long-term stability ...

located in 49 states and containing approximately 47.2 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol "ADC".

The theory behind antibody drug conjugates (ADCs) is simple yet elegant: by combining the specificity of a monoclonal antibody with the cytotoxicity of a potent small molecule drug, ADCs can ...

Antibody-drug conjugates (ADCs) are a class of biologic drugs designed for targeted treatment of cancer. The treatments combine monoclonal antibodies (mAbs) alongside potent anti-cancer agents ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...